Shares of Novavax Inc. NVAX, +5.38% jumped 1.7% in premarket trading on Wednesday after the company said its COVID-19 vaccine boosted antibody levels when used as a booster. The data, from a Phase 3 clinical trial, tested a third shot in adults who had been vaccinated with Novavax’s initial series of shots 8 or 11 months prior. The company also said the study showed that a third shot in teens boosted neutralizing antibody titers 2.7 times higher than what was reported after primary vaccination. Novavax’s stock has tumbled 86.7% this year, while the broader S&P 500 SPX, +0.25% is down 24.7%.
